Heroin Adulterated with the Novel Synthetic Cannabinoid, 5F-MDMB-PINACA: A Case Series by Ershad, Muhammed et al.
UC Irvine
Clinical Practice and Cases in Emergency Medicine
Title
Heroin Adulterated with the Novel Synthetic Cannabinoid, 5F-MDMB-PINACA: A Case Series
Permalink
https://escholarship.org/uc/item/6fz2q2tm
Journal
Clinical Practice and Cases in Emergency Medicine, 4(2)
ISSN
2474-252X
Authors
Ershad, Muhammed
Dela Cruz, Maricel
Mostafa, Ahmed
et al.
Publication Date
2020
DOI
10.5811/cpcem.2020.2.45060
License
https://creativecommons.org/licenses/by/4.0/ 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Volume IV, no. 2: May 2020 121 Clinical Practice and Cases in Emergency Medicine
Case series
 
Heroin Adulterated with the Novel Synthetic Cannabinoid, 
5F-MDMB-PINACA: A Case Series
 
Muhammed Ershad, MD*
Maricel Dela Cruz, MD*
Ahmed Mostafa, MD*
Muhammad M. Khalid, MD*
Ryan Arnold, MD†
Richard Hamilton, MD†
 
Section Editors: Steven Walsh, MD           
Submission history: Submitted September 3, 2019; Revision received February 20, 2020; Accepted February 21, 2020 
Electronically published April 23, 2020         
Full text available through open access at http://escholarship.org/uc/uciem_cpcem   
DOI: 10.5811/cpcem.2020.2.45060 
Introduction: Heroin can be adulterated with various substances that may or may not have 
pharmacological effects. Here we report a case series of 8 patients who presented to the emergency 
department after overdose with intravenous heroin preparation adulterated with the synthetic cannabinoid 
methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (5F-MDMB-PINACA).
Case Series: Except for one patient, all of them presented with a typical initial opioid toxidrome 
consisting of central nervous system and respiratory depression along with pinpoint pupils. Naloxone 
was given to them, triggering severe agitation and combative behavior along with overlapping 
features of anticholinergic and sympathomimetic toxidrome. All patients required multiple doses of 
benzodiazepines. Three were successfully treated with physostigmine.
Discussion: 5F-MDMB-PINACA is a synthetic cannabinoid that was added to heroin in samples 
obtained from patients reported in this case series. Patients demonstrated significant agitation after 
receiving naloxone for opioid toxidrome, presumably because of the removal of the depressant effect 
of opioids, which unmasked the excitatory effects of the synthetic cannabinoids. Three patients 
required physostigmine along with the benzodiazepines for control of their agitation, urine retention 
and abnormal vitals, suggesting the possibility of an anticholinergic toxidrome to have developed in 
these patients.
Conclusion: Heroin contaminated with 5F-MDMB-PINACA exhibits variable severities of 
anticholinergic effects, some on presentation and others only after opiate antagonism. [Clin Pract 
Cases Emerg Med. 2020;4(2):121–125.]
Keywords: synthetic cannabinoids; heroin; physostigmine.
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INTRODUCTION
Heroin is often adulterated with a variety of substances 
including baking soda, caffeine, crushed analgesics, and 
scopolamine.1 We present a consecutive patient case series 
with similar presentations after overdose with intravenous 
(IV) heroin adulterated with the synthetic cannabinoid (SC) 
methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-
3,3-dimethylbutanoate (5F-MDMB-PINACA). Within three 
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What do we already know about this clinical 
entity? 
Synthetic cannabinoids (SC) may be added 
as adulterants to opiates sold on the street, 
which can contribute to unpredictable 
clinical consequences. 
What makes this presentation of disease 
reportable? 
We report a case series of eight patients 
who had predominantly anticholinergic 
features after using heroin containing the SC 
5F-MDMB-PINACA. 
What is the major learning point? 
Patients using heroin containing SCs may 
exhibit severe agitation and hyperactive 
behavior following naloxone administration. 
How might this improve emergency 
medicine practice? 
Consider using physostigmine along with 
benzodiazepines in treating patients with 
severe agitation following naloxone-induced 
reversal of an opioid toxidrome.
months, eight patients presented to the emergency department 
(ED) after use of IV heroin with symptoms consistent with 
anticholinergic toxicity and variable requirement for naloxone 
administration by emergency medical services (EMS). 
CASE SERIES
Case 1
A 28-year-old man with a past medical history of bipolar 
disorder and polysubstance abuse including IV heroin, 
presented to the hospital by EMS after being found at home 
unresponsive. Family members found packets of drugs near 
the patient labelled “Santa Muerte (Image 1). On arrival, 
vital signs included a heart rate (HR) of 122 beats per 
minute, blood pressure (BP) 134/78 millimeters of mercury 
(mm Hg), respiratory rate (RR) of 38 breaths per minute, 
oral temperature 98.2 degrees Fahrenheit (F), and oxygen 
saturation (SpO2) 78% on non-rebreather mask. Physical 
exam included tachycardia, flushing, dry mucous membranes 
and mydriasis. The patient was initially given two milligrams 
(mg) of intranasal (IN) naloxone in the field by EMS 
secondary to central nervous system (CNS) and respiratory 
depression, with no response. He was given a second dose of 
two mg IN naloxone and became agitated and combative. 
The patient was intubated upon ED arrival for hypoxic 
respiratory failure. Chest radiograph showed signs of aspiration 
pneumonitis, which developed into acute respiratory distress 
syndrome (ARDS) requiring venovenous extracorporeal 
membrane oxygenation (VV-ECMO). Head computed 
tomography was negative for acute intracranial abnormality. 
Complete blood count (CBC) and basic metabolic panel (BMP) 
were unremarkable. Urine drug screen immunoassay was 
positive for cocaine, opiates, fentanyl, tetrahydrocannabinol 
(THC) and benzodiazepines. Comprehensive drug screen 
of the serum by liquid chromatography tandem mass 
spectrometry (LC-MS-MS) was positive for cocaine, heroin, 
6-monoacetylmorphine (6-MAM), fentanyl, THC, and 
alprazolam. The patient remained intubated on VV-ECMO 
for 12 days, after which he was extubated, removed off of 
VV-ECMO, and discharged on day 17. Laboratory analysis 
of the patient’s confiscated drug by gas chromatography-mass 
spectrometry (GC-MS) and liquid chromatography quadrupole 
time-of-flight  mass spectrometry (LCQ-TOF-MS) was positive 
for the novel SC 5F-MDMB-PINACA, heroin, and fentanyl. 
Case 2
A 25-year-old man with a past medical history of IV 
heroin use, presented to the ED by EMS after IV heroin use. 
The patient initially had CNS and respiratory depression in 
the field and was first given two mg of IN naloxone with no 
response, followed by a second dose of two mg IN naloxone, 
which made him anxious and tachycardic. Vital signs on 
Image 1. Packets of “Santa Muerte,” a street heroin adulterated 
with synthetic cannabinoid, that were retrieved from a patient 
found unresponsive at home.
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arrival to the ED included a HR of 102 beats per minute, BP 
of 146/89 mmHg, RR 24 breaths per minute, SpO2 98% on 
room air, and oral temperature 97.5º F. Physical exam was 
positive for flushing, tachycardia, and agitation. The patient 
was given 4 mg of lorazepam IV in the ED. He admitted to the 
use of an adulterated heroin “Santa Muerte.” CBC and BMP 
were unremarkable. Urine drug screen immunoassay was 
positive for opiates, amphetamine, barbiturates and cocaine. 
Symptoms improved after benzodiazepine treatment, IV 
fluids, and supportive care. He was admitted for 24 hours and 
discharged the following day with no further complications. 
Laboratory analysis of the patient’s confiscated drug by GC-
MS and LCQ-TOF was positive for the novel SC 5F-MDMB-
PINACA, heroin, and fentanyl.
Case 3
A 31-year-old man with a past medical history of IV 
heroin use, presented to the ED by EMS for CNS and 
respiratory depression after IV heroin use. The patient’s 
girlfriend provided the history that the patient was using a 
new type of heroin called “Santa Muerte.” The patient was 
given a total of four mg IN naloxone in the field, after which 
he became agitated, combative, and tachycardic. His vital 
signs on arrival included a HR of 163 beats per minute, BP 
of 131/81 mmHg, RR of 29 breaths per minute, SpO2 99% 
on room air, and oral temperature 98.8 degrees F. While 
in the ED, he continued to be agitated and combative. On 
examination, he was tachycardic and flushed with dilated 
pupils and a palpable full bladder in the suprapubic region. 
The patient was given a total of 10 mg of lorazepam with 
minimal improvement of his agitation, and he was later 
intubated for airway protection. Complete blood count (CBC) 
and basic metabolic panel (BMP) were unremarkable, and 
urine drug screening immunoassay was positive for opiates. 
Serum comprehensive drug screen by LC-MS-MS was 
positive for heroin, 6-MAM, fentanyl, and negative for any 
SCs. The patient later developed ARDS, requiring increased 
ventilator setting and was transferred to a tertiary center 
for VV-ECMO. Specialty laboratory testing of the patient’s 
confiscated drug by GC-MS and LCQ-TOF was positive for 
the novel SC 5F-MDMB-PINACA, heroin, and fentanyl. 
Case 4
A 25-year-old man presented to the hospital by EMS 
after IV heroin use. The patient was found with a drug packet 
labeled “Santa Muerte” in his pocket and had CNS and 
respiratory depression. He was given a total of four mg of IN 
naloxone, after which he became flushed, tachycardic, and 
agitated with dilated pupils. On arrival to the ED, his HR 
was 158 beats per minute, BP was 215/158 mmHg, RR was 
26 breaths per minute, SpO2 was 99% on room air, and oral 
temperature was 102.1º F. On exam, he had urinary retention 
and anhidrosis. He was given four mg of lorazepam and 
two mg of IV physostigmine, which treated his agitation. 
There was also marked improvement in anhidrosis and urine 
retention. He was admitted for 24 hours and discharged the 
following day with no further complications. Urine drug 
screen was positive for cocaine, opiates, and THC. Serum 
comprehensive toxicology analysis by LC-MS-MS was 
positive for 5F-MDMB-PICA(5F-ADB), heroin, 6-MAM, 
and fentanyl. Laboratory analysis of the patient’s confiscated 
drug by GC-MS and LCQ-TOF was positive for the novel SC 
5F-MDMB-PINACA, heroin, and fentanyl.
Case 5
A 45-year-old man was found down in the field agitated 
and tachycardic. On arrival to the ED, his HR was 124 
beats per minute, BP 140/82 mm Hg, RR 22 breaths per 
minute, oxygen saturation 99%, and oral temperature 99.3º 
F. On exam, he had pinpoint pupils with flushing of skin. 
He received midazolam five mg and olanzapine 20 mg 
intramuscular followed by diazepam 10 mg IV after which he 
calmed down. He was eventually started on dexmedetomidine 
infusion when his agitation returned. He was admitted for 24 
hours and discharged the following day with no complications. 
Urine drug screen was positive for opiates and fentanyl. He 
was found with a drug packet named “50 CAL” (Image 2), 
which was sent for GC-MS and LCQ-TOF and was found to 
be positive for 5F-MDMB-PINACA, heroin, and fentanyl.
Case 6
A 36-year-old man was found lying in the street 
unresponsive. He received eight mg of naloxone IN after 
which he became agitated. On arrival to the ED, his HR was 
130 beats per minute, BP 160/100 mm Hg, RR 24 breaths per 
minute, oxygen saturation 95% on 100 % oxygen, and oral 
temperature 98.6º F. Initial physical examination revealed 
Image 2. A “50 CAL” drug packet retrieved from a patient, which 
contained heroin, synthetic cannabinoid, and fentanyl.
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restlessness, confusion, and picking behavior. Patient also 
had bilaterally dilated pupils with urine retention on point-of-
care ultrasound. Considering an anticholinergic toxidrome, 
the emergency provider administered physostigmine two mg 
IV with improvement in agitation, picking behavior, urine 
retention, and relative constriction in pupillary diameter. 
He had received multiple doses of benzodiazepines prior 
to physostigmine. He was eventually intubated due to risk 
of aspiration from vomiting in the setting of altered mental 
status. His mental status and vitals improved the next day, 
following which he was extubated. CBC and BMP were 
unremarkable and urine drug screen was positive for opiates 
and fentanyl. The patient was found with a blue packet labeled 
“50 CAL,” which was found to be positive for fentanyl, 
heroin, and 5F-MDMB-PINACA on GC-MS and LCQ-TOF. 
Case 7
A 23-year-old woman was brought to the ED with severe 
agitation and combative behavior. Her initial vitals were HR 
156 beats per minute, BP 147/64 mm Hg, RR 20 breaths per 
minute, and oral temperature 101.5º F. Examination revealed 
bilaterally dilated pupils, flushed and dry skin, and urine 
retention on point-of-care ultrasound. The patient received 
Lorazepam four mg IV and physostigmine two mg IV after 
which her agitation subsided, urine retention improved, 
pupillary diameter decreased, and skin appeared less flushed 
and less dry. CBC and BMP were unremarkable while her 
urine drug screen was positive for opiates and fentanyl. She 
was admitted to the floor and discharged the next day. The 
patient reported consuming a substance from packets labeled 
“50 CAL.” The drug packets were not available for analysis. 
We were also unable to send her serum or urine for further 
comprehensive toxicology analysis. 
Case 8
A 27-year-old man was brought to the ED after IV heroin 
use. He was found to be in respiratory and CNS depression 
with pinpoint pupils in the field by the EMS. Naloxone 
four mg IN was given after which he became agitated. 
His vitals were HR 130 beats per minute, BP 130/94 mm 
Hg, RR 22 breaths per minute, and temperature of 99º F. 
Initial examination revealed dilated pupils, dry oral mucous 
membrane, and flushed skin. He received lorazepam 4 mg IV 
and physostigmine two mg IV after which he calmed down, 
pupils returned back to normal size, and heart rate came down 
to normal; he was admitted to the floor. Urine drug screen was 
positive for opiates and fentanyl. He reported having ingested 
drugs from packets labeled “Nick” and “50 CAL,” but they 
were unavailable for analysis. 
DISCUSSION
Heroin has been historically adulterated with a variety of 
substances including baking soda, caffeine, acetaminophen, 
diphenhydramine, scopolamine, fentanyl, and clenbuterol.1 These 
adulterants are usually added to increase profits by incorporating 
any substance that looks like the original substance and/or would 
have the same effect. In the months of April and August 2018, 
consumption of heroin that had been laced with the newer SC 
5F-MDMB-PINACA gave rise to a series of patients presenting 
to our ED with unique clinical manifestations.
SCs, by themselves, have been widely used as drugs of 
abuse since the early 2000s. They have been found to have 
more adverse clinical presentations than the active compound 
marijuana itself, owing to its full agonistic action on the 
cannabinoid receptor type 1 (CB1) and cannabinoid receptor 
type 2 (CB2) receptors, as compared to marijuana, which is 
only a partial agonist.2 Clinical effects of SC overlap with 
anticholinergic and sympathomimetic toxidromes.3,4 There 
have also been reported fatalities with SCs including 5F-ADB, 
5F-PB-22, and AB-CHMINACA.5
The patients reported in our case series took opioids 
containing 5F-MDMB-PINACA (Figure), which is a new 
generation SC. Except for patient 5, all of them presented 
with a typical initial opioid toxidrome consisting of CNS 
and respiratory depression along with pinpoint pupils. 
Naloxone, an opioid antagonist, was given to them, which 
triggered severe agitation and combative behavior along with 
overlapping features of anticholinergic and sympathomimetic 
toxidrome. This was presumably because of the removal of the 
depressant effect of opioids by the administration of naloxone 
that unmasked the effects of SC. 
All the patients required multiple doses of 
benzodiazepines. Three of the eight patients were 
successfully treated with physostigmine, which 
helped control the abnormal psychomotor activity and 
anticholinergic manifestations.  
The initial urine drug screen test used for all eight 
patients was an immunoassay-based screening test. Apart 
from morphine (opiates), it tests for fentanyl, buprenorphine, 
Figure. Chemical structure of the synthetic cannabinoid 
methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-
dimethylbutanoate.
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methadone, tramadol, cocaine, oxycodone, phencyclidine, 
amphetamines, barbiturates, benzodiazepines, and 
cannabinoids. The comprehensive serum drug screen 
performed in cases 1, 3 and 4 was through LC-MS-MS, which 
is an exceedingly sensitive and specific analytical technique 
that can precisely estimate the identities and concentrations of 
molecules within a sample.
The seized drug packets were analyzed at the Center 
for Forensic Science Research and Education, using GC-
MS and LCQ-TOF. The samples were prepared using acid/
base extraction prior to the analysis.6 The drug packets that 
were analyzed at this facility did not turn positive for any of 
the anticholinergic agents, thereby leading us to conclude 
that 5F-MDMB-PINACA potentially has anticholinergic 
manifestations that seem to be responding to physostigmine in 
our clinical experience.
CONCLUSION
Heroin contaminated with 5F-MDMB-PINACA 
exhibits variable severities of anticholinergic effects, some 
on presentation and others only after opiate antagonism. 
Synthetic cannabinoids affect cannabinoid CB1 and CB2 
receptors, potentially causing adrenergic stimulation, 
sedation, hallucinations, catecholamine release, and severe 
tachycardia.2-4 It is also possible that synthetic cannabinoids 
and/or their metabolites interact directly with acetylcholine 
receptors to cause anticholinergic effects. In our case 
series, we found that physostigmine was effective in 
reversing the anticholinergic effects and agitation in three 
out of the eight patients. 
The authors attest that their institution requires neither 
Institutional Review Board approval, nor patient consent for 
publication of this case report. Documentation on file.
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